Bulletin
Investor Alert

New York Markets After Hours

Acorda Therapeutics Inc.

NAS: ACOR

GO
/marketstate/country/us

After Hours

/zigman2/quotes/208738192/composite

$

0.58

Change

-0.04 -6.02%

Volume

Volume 491,893

Sep 25, 2020, 4:45 p.m.

Real time quotes

/zigman2/quotes/208738192/composite

Today's close

$ 0.47

$ 0.62

Change

+0.14 +30.13%

Day low

Day high

$0.47

$0.86

Open
Open: 0.48

52 week low

52 week high

$0.42

$3.15

Open

Market cap

$22.67M

Average volume

1.88M

P/E ratio

N/A

Rev. per Employee

$994,584

EPS

-4.67

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/acor

MarketWatch News on ACOR

  1. Acorda Therapeutics downgraded to underweight from neutral at J.P. Morgan

    8:13 a.m. Oct. 24, 2019

    - Tomi Kilgore

  2. Here are the stocks that have soared and sunk the most in 2019

    11:21 a.m. Oct. 2, 2019

    - Philip van Doorn

  3. These 6 stocks in the S&P 1500 have more than doubled in 12 months

    7:28 a.m. July 13, 2019

    - Philip van Doorn

  4. Acorda Therapeutics started at neutral with $12 stock price target at Wedbush

    7:35 a.m. May 23, 2019

    - Tomi Kilgore

  5. Acorda Therapeutics stock price target cut to $15 from $18 at Oppenheimer

    8:31 a.m. March 25, 2019

    - Tomi Kilgore

  6. Elliott Associates Wants Bit Changes at eBay

    2:39 p.m. Feb. 27, 2019

    - Barron's Online

  7. Engaged Capital Helps Rethink Benchmark Electronics

    1:40 p.m. Feb. 28, 2019

    - Barron's Online

  8. Acorda Therapeutics reiterated as underperform at Raymond James

    8:22 a.m. Dec. 26, 2018

    - Ciara Linnane

  9. Acorda Therapeutics' stock extends gains, surges 17.5% in premarket trade

    9:27 a.m. Dec. 24, 2018

    - Tomi Kilgore

  10. Acorda Therapeutics' stock indicated up 16% premarket after FDA OKs Parkinson's disease treatment

    8:38 a.m. Dec. 24, 2018

    - Tomi Kilgore

  11. Acorda Therapeutics' Inbrija Parkinson's treatment approved by FDA

    8:10 a.m. Dec. 24, 2018

    - Tomi Kilgore

  12. ValueAct’s Moves Into ESG Investing

    12:58 p.m. Dec. 24, 2018

    - Barron's Online

  13. Carl Icahn Opposes Deal as Proposed by Michael Dell

    6:47 p.m. Oct. 20, 2018

    - Barron's Online

  14. Acorda says FDA has extended review period for Parkinson's disease treatment

    7:35 a.m. Sept. 13, 2018

    - Ciara Linnane

  15. Acorda shares slide 17% premarket

    7:35 a.m. Sept. 13, 2018

    - Ciara Linnane

  16. Not Just a Checkout Button

    11:35 a.m. July 30, 2018

    - Barron's Online

  17. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/acor

Other News on ACOR

  1. Steven Cohen Shifts Into a Higher Gear With Bicycle Therapeutics

    11:44 a.m. Sept. 16, 2020

    - GuruFocus.com

  2. 10-Q: ACORDA THERAPEUTICS INC

    6:12 a.m. Aug. 10, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  3. 10-Q: ACORDA THERAPEUTICS INC

    5:42 p.m. May 8, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  4. Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?

    11:49 a.m. April 24, 2020

    - Zacks.com

  5. Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study

    12:37 p.m. April 7, 2020

    - Zacks.com

  6. Loading more headlines...
/news/pressrelease/company/us/acor

Press Releases on ACOR

  1. 4 Top Penny Stocks Reaching New Highs Today; 1 Up 60%+ In September

    3:00 p.m. Today

    - Penny Stocks

  2. Multiple Sclerosis Therapeutics Market Global Research and Clinical Survey Report 2020 to 2025

    12:29 a.m. Today

    - Market Insight Reports

  3. Aravive Appoints Michael W. Rogers to Board of Directors

    7:00 a.m. Sept. 17, 2020

    - GlobeNewswire

  4. Aravive Appoints Michael W. Rogers to Board of Directors

    7:00 a.m. Sept. 17, 2020

    - GlobeNewswire

  5. Spinal Cord Trauma Treatment Market Research and Clinical Analysis 2020

    9:28 a.m. Aug. 28, 2020

    - Market Insight Reports

  6. Loading more headlines...

Rates »

Link to MarketWatch's Slice.